VIAMUNE, INC.
Athens, GA · Biotech · Private
Chemoenzymatically synthesized human milk oligosaccharides (HMOs) library for high-throughput screening and therapeutic development
- Grants
- $1.6M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Targeting aberrant glycopeptide tumor antigens for generation of novel cancer therapeutics with enhanced selectivity and utility | $436,070 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting aberrant glycopeptide tumor antigens for generation of novel cancer therapeutics with enhanced selectivity and utility | $212,853 | |
| Federal grant | Department of Health and Human Services · Phase I · Chemoenzymatic synthesis of a human milk oligosaccharide array for discovery of therapeutic leads | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Chemoenzymatic synthesis of a human milk oligosaccharide array for discovery of therapeutic leads | $150,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Expanding the Glycomics toolbox: Chemo-enzymatic synthesis of well-defined N-glycan standards | $274,486 | |
| Federal grant | Department of Health and Human Services · Phase I · Expanding the Glycomics toolbox: Chemo-enzymatic synthesis of well-defined N-glycan standards | $274,486 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1453 | Surf Lakes Global, Inc. | — | $720K |
| 1454 | Aion Therapeutic Inc. | — | $5.9M |
| 1455 | Nistron, L.L.C. | — | — |
| 1456 | VIAMUNE, INC. | — | — |
| 1457 | Neuralexo, LLC | — | — |
| 1458 | MICROBITYPE LLC | — | — |
| 1459 | ArTara Therapeutics, Inc. | — | $4.2M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.